Antibody‑drug conjugate specialist Tubulis closed a large Series C financing—reported at roughly €308 million (about $356 million)—to accelerate clinical development of TUB‑040 and its ADC pipeline. The funds will support testing in additional indications, earlier lines of therapy, and broader pipeline work ahead of upcoming clinical data readouts. The company plans to present first clinical data from TUB‑040 in platinum‑resistant ovarian cancer at an upcoming oncology meeting and will use proceeds to expand trials into other tumor types. Tubulis emphasised in statements that in‑house optimization of ADC components aims to improve biophysical properties and allow higher drug‑to‑antibody ratios. Investors and analysts flagged the round as one of the larger European biotech financings of the year, signaling strong market interest in next‑generation ADC platforms and the willingness of private capital to underwrite expensive clinical translations for differentiated oncology modalities.